Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
Shih-Ern YaoLee TripconyKaren SandayJessica RobertsonLewis PerrinNaven ChettyRussell LandAndrea GarrettAndreas ObermairMarcelo NascimentoAmy TangNisha JagasiaPiksi SinghJim NicklinPublished in: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society (2020)
Survival outcomes do not appear to be worse for patients treated with neoadjuvant chemotherapy if cytoreduction surgery is delayed beyond three cycles. In advanced epithelial ovarian cancer patients the imperative to achieve complete surgical cytoreduction remains gold standard, irrespective of surgical timing, for best survival benefit.